Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, randomized, parallel-group study to compare the
efficacy,pharmacodynamics (PD), pharmacokinetics (PK), safety, and immunogenicity of BAT2506
versus Simponi® in participants with active PsA.
The study will consist of up to 4-week Screening Period, a 52-week Treatment Period, and a
8-week Safety Follow-up Period.